Pediatric ethics
Executive Summary
FDA's Pediatric Advisory Subcommittee on Pediatric Ethics will meet June 9-10 to discuss clinical investigations that involve greater than minimal risk but present the prospect of direct benefits to individual subjects. The June 9 discussion will be illustrated with hypothetical cases of research involving HIV vaccines in adolescents and controlled trials of inhaled corticosteroids in children with asthma, and the June 10 discussion with a hypothetical case of research using stem cells for treating periventricular white matter injury in children
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.